Fenske et al., 2014 - Google Patents
15 Medical Applications of Lipid NanoparticlesFenske et al., 2014
View PDF- Document ID
- 6775053430885876360
- Author
- Fenske D
- Cullis P
- Publication year
- Publication venue
- Liposomes, Lipid Bilayers and Model Membranes: From Basic Research to Application
External Links
Snippet
301 15.4 Recent Advances in LNP for Delivery of Conventional Drugs and siRNA......................... 303 15.5 Medical Applications of LNP............................................................. .................................. 306 15.5. 1 LNP Encapsulating Anticancer Drugs …
- 150000002632 lipids 0 title description 86
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
- A61K47/48792—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a colloid, emulsion, i.e. having at least a dispersed/continuous oil phase and a dispersed/continuous aqueous phase, dispersion or suspension
- A61K47/48815—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a colloid, emulsion, i.e. having at least a dispersed/continuous oil phase and a dispersed/continuous aqueous phase, dispersion or suspension the form being a liposome, i.e. a bilayered vesicle, having its surface modified by covalent attachment or complexation of the pharmacologically or therapeutically active agent and/or modifying agent.
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48007—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ickenstein et al. | Lipid-based nanoparticle formulations for small molecules and RNA drugs | |
Large et al. | Liposome composition in drug delivery design, synthesis, characterization, and clinical application | |
Apolinário et al. | Lipid nanovesicles for biomedical applications:‘What is in a name’? | |
Wan et al. | Lipid nanoparticle delivery systems for siRNA-based therapeutics | |
Laura Immordino et al. | Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential | |
MacLachlan | Liposomal formulations for nucleic acid delivery | |
Leung et al. | Lipid nanoparticles for short interfering RNA delivery | |
Maurer et al. | Developments in liposomal drug delivery systems | |
Obeid et al. | Lipid-based nanoparticles for cancer treatment | |
AU2010227549B2 (en) | Pharmaceutical composition containing a drug and siRNA | |
Abbasi et al. | What we need to know about liposomes as drug nanocarriers: an updated review | |
US20190328665A1 (en) | Liposome compositions encapsulating modified cyclodextrin complexes and uses thereof | |
Ali et al. | Microfluidics for development of lipid nanoparticles: paving the way for nucleic acids to the clinic | |
Qian et al. | Pharmacokinetics and disposition of various drug loaded liposomes | |
Palmer et al. | Transfection properties of stabilized plasmid–lipid particles containing cationic PEG lipids | |
WO2008038291A1 (en) | Combination of liposomal anti-cancer drugs and lysosome/endosome ph increasing agents for therapy | |
Nele et al. | Lipid nanoparticles for RNA delivery: Self-assembling vs driven-assembling strategies | |
Fenske et al. | 15 Medical Applications of Lipid Nanoparticles | |
Eş et al. | Engineering aspects of lipid-based delivery systems: In vivo gene delivery, safety criteria, and translation strategies | |
Sharma et al. | Liposomes: vesicular system an overview | |
Bulbake et al. | Liposomal drug delivery system and its clinically available products | |
Sarker | Sculpted amphiphilic liposomal particles for modifiable medicinal applications | |
Amarandi et al. | Liposomal-based formulations: A path from basic research to temozolomide delivery inside glioblastoma tissue, Pharmaceutics, 2022, vol. 14 | |
Obeid | Formulation of non-ionic surfactant vesicles for therapeutic delivery of siRNA in cancer treatment | |
Lúcio et al. | General Aspects of a Multifunctional Nanosystem |